S100A11 and Miyoshi myopathy: In a recent study, S100A4, S100A10, and S100A11 showed significant upregulation in MM non-responding versus responding patients treated with a combined regimen, including daratumumab, carfilzomib, lenalidomide, and dexamethasone (KARA-KRD), and their overexpression were also involved in clonal evolution of a primary refractory MM patient responding to KARA-KRD treatment (Cohen et al., 2021).